Vicky Brock, from Vistalworks, shares how the ‘NCSC For Startups’ programme has supported her company in creating solutions to address illegal online trade.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
